Last Updated: November 16, 2026

Patent: 10,786,557

« Back to Dashboard


Summary for Patent: 10,786,557
Title:Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
Inventor(s): Broom; Colin (Devon, PA), Dayno; Jeffrey (Maple Glen, PA)
Assignee: SHIRE VIROPHARMA LLC (Lexington, MA)
Application Number:16/293,134
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 10,786,557: Claims, Exclusivity, Litigation Risk and C1-INH Patent Landscape in Neuromyelitis Optica

US Patent 10,786,557 protects a narrow clinical-use method: administering C1-esterase inhibitor during an acute neuromyelitis optica or neuromyelitis optica spectrum disorder attack and restoring symptoms to pre-attack levels. The patent does not claim C1-INH as a molecule, a formulation, a manufacturing process, or a broad treatment for complement-mediated disease.

The principal commercial product implicated by the claims is Cinryze, a human plasma-derived C1-INH product. Cinryze is FDA-approved for routine prophylaxis against hereditary angioedema attacks, not for NMO or NMOSD. The patent therefore creates method-of-use exposure around off-label acute NMO treatment, but it does not create an Orange Book-style barrier against competing C1-INH products or biosimilars.

What does US Patent 10,786,557 claim?

The patent contains 18 claims directed entirely to methods of treatment or prevention. Independent claims 1 and 18 define the core scope.

Claim element Claim 1 Claim 18
Disease NMO or NMOSD NMO or NMOSD
Product C1-esterase inhibitor C1-esterase inhibitor
Timing During an active CNS attack At onset of an active CNS attack
Therapeutic objective Treat or delay progression Prevent or delay progression
Required result Symptoms decrease to pre-attack levels Symptoms decrease to pre-attack levels
Product source Expanded by claim 2 to human plasma-derived or recombinant C1-INH No express source limitation
Combination therapy Covered in dependent claims Not expressly required

The core infringement theory requires more than use of C1-INH in an NMO patient. The relevant treatment must satisfy the claimed disease, timing, therapeutic purpose and clinical-result limitations.

What products fall within the patent claims?

Claim 2 covers both:

  • Human plasma-derived C1-INH, including Cinryze and potentially other plasma-derived C1-INH products.
  • Recombinant C1-INH, including products such as Ruconest if used in the claimed NMO setting.

Claim 4 narrows the use to Cinryze for NMO. The claim does not cover only Cinryze, however. Claim 1 is broader because it covers C1-INH generally, while claim 2 identifies plasma-derived and recombinant forms.

The patent does not require a specific dose, route of administration, infusion schedule, concentration, formulation, device or treatment duration in the independent claims. That increases practical breadth within the defined acute-attack setting.

How are the dependent claims structured?

The dependent claims add disease subtypes, combination therapies and treatment timing.

Claims Subject matter
2 Human plasma-derived or recombinant C1-INH
3 NMO, Devic's disease, longitudinally extensive transverse myelitis, optic neuritis and related disorders
4 Cinryze for NMO
5 Additional biologically active agent
6 Plasmapheresis and/or intravenous immunoglobulin
7-8 Concurrent or sequential administration with plasmapheresis or IVIG
9 Mycophenolate, rituximab and/or eculizumab
10-11 Concurrent or sequential administration with those agents
12 Early acute phase
13 Short-term treatment
14-15 Concurrent or sequential administration of C1-INH and another biologically active agent
16 Early acute phase under claim 1
17 Short-term administration under claim 1
18 Prevention or delay at onset of an active attack

Claim 3 is potentially important because it includes a long list of NMO-related clinical presentations, including AQP4-antibody-seronegative disease. Its breadth is limited by dependency on claim 1. The treatment still must involve C1-INH during an active attack and produce the claimed reduction in symptoms.

Claims 5 through 15 create combination-treatment positions. They cover C1-INH with plasmapheresis, IVIG, mycophenolate, rituximab or eculizumab. They do not necessarily require that the additional treatment itself be novel.

What is the patent’s likely expiration date?

The patent issued in 2020 and claims priority to an earlier U.S. filing in the 2013 period. On the ordinary U.S. patent-term calculation, the family has a nominal expiration in the 2033-2034 range, subject to patent-term adjustment and any terminal disclaimer applicable to the issued patent family.[1]

Event Date or period
Earliest family priority 2013 period
U.S. patent grant 2020
Nominal 20-year term Approximately 2033-2034
Patent-term adjustment Must be confirmed from the USPTO patent record
Patent-term extension No established FDA-based extension for the NMO method claim
Regulatory exclusivity No NMO approval-based exclusivity identified

The most reliable expiration date is the term information in USPTO Patent Center and the front-page patent-term statement. A patent issued from a continuation can retain the parent’s priority date while receiving a term measured from the earliest effective nonprovisional filing date. The grant date does not determine expiration.

What is the FDA and Orange Book status of the patent?

US Patent 10,786,557 is not an Orange Book product patent in the conventional sense.

Cinryze is a biologic product regulated under a biologics license application, not an NDA-listed small-molecule product. FDA identifies Cinryze as a human plasma-derived C1-esterase inhibitor approved for routine prophylaxis against hereditary angioedema attacks.[2] The NMO use in US Patent 10,786,557 is not the approved indication.

The relevant regulatory consequences are:

  1. A generic applicant cannot use a conventional ANDA Paragraph IV certification to challenge the patent as it would for an Orange Book-listed small molecule.
  2. A biosimilar applicant would proceed under the Public Health Service Act pathway, not the Hatch-Waxman ANDA pathway.
  3. The patent is not converted into a blocking product patent merely because Cinryze is the specifically named product in claim 4.
  4. FDA approval of C1-INH for NMO would be separate from patent validity and infringement.

The patent can still be asserted against a provider, manufacturer or commercial sponsor whose conduct practices the claimed NMO treatment method. Its enforcement position is different from an Orange Book-listed method-of-use patent.

Does Cinryze have FDA approval for NMO or NMOSD?

No. Cinryze is approved for routine prophylaxis against hereditary angioedema attacks. The FDA label does not establish approval for acute NMO or NMOSD attacks.[2]

C1-INH is biologically relevant to complement activation. NMO pathophysiology, particularly AQP4-antibody-positive disease, involves antibody-mediated astrocyte injury, complement activation and inflammatory damage. That mechanism provides a biological rationale for acute complement inhibition, but a mechanistic rationale is not equivalent to an FDA-approved indication.

The commercial distinction is material:

  • Cinryze use in NMO would generally be off-label unless a later supplemental approval changes the label.
  • The patent’s claims are directed to the NMO treatment method, regardless of whether the product label includes NMO.
  • An insurer, hospital or physician may face reimbursement and protocol issues separate from patent infringement.

What prior-art and validity issues affect the patent?

The strongest validity questions concern the combination of known C1-INH biology, NMO complement activation and clinical use during acute attacks.

Written description and enablement

The claims cover both treatment and prevention, multiple C1-INH sources, numerous NMO phenotypes and combinations with established therapies. A validity challenge could argue that the specification does not adequately support the full breadth of:

  • All human plasma-derived C1-INH products.
  • All recombinant C1-INH products.
  • AQP4-seronegative NMO.
  • Prevention or delay of progression.
  • Restoration of symptoms to pre-attack levels.
  • Every combination with plasmapheresis, IVIG, rituximab, mycophenolate or eculizumab.

The counterargument is that the claims are treatment-method claims directed to a defined disease and a common biological mechanism, and that clinical examples or treatment protocols in the specification may support the claimed use.

Obviousness

Potential prior art would include:

  • Earlier reports of complement activation in NMO.
  • C1-INH use in complement-mediated inflammatory conditions.
  • Case reports or clinical protocols involving C1-INH in acute NMO.
  • Existing acute NMO treatment using plasma exchange, IVIG or corticosteroids.
  • Publications identifying C1-INH as a complement-pathway inhibitor suitable for inflammatory neurologic disease.

An obviousness challenge would need to show a reason to combine those teachings with a reasonable expectation that C1-INH would reduce acute NMO symptoms to pre-attack levels. The clinical-response limitation may provide the patentee with a stronger position if the record shows an unexpected or clinically meaningful result.

Indefiniteness

The phrase “decreases symptoms of NMO or NMOSD to pre-attack levels” creates a potential indefiniteness issue. Symptoms such as visual acuity, motor strength, sensory loss and bladder dysfunction may be measured differently. The claim does not specify:

  • The symptom to be measured.
  • The baseline measurement.
  • The time point for comparison.
  • The clinical scale.
  • Whether complete or partial restoration is required.

A court could interpret the phrase in light of the specification and ordinary clinical practice. If the patent provides objective pre-attack measurements or a defined assessment protocol, the vulnerability decreases. If not, the limitation may generate claim-construction and enablement disputes.

Written description of claim 18

Claim 18 is particularly exposed because it recites “preventing or delaying the progression” while also requiring administration at the onset of an active attack and a reduction of symptoms to pre-attack levels. A challenger may argue that the claim combines acute rescue treatment with a broader prophylactic objective that lacks adequate written-description support.

How strong is the patent estate?

The estate is commercially focused but technically narrow.

Strength Assessment
Product coverage Moderate; covers C1-INH use, not the molecule itself
Acute NMO coverage Stronger; timing and disease limitations define a focused use
Formulation coverage Weak; no dedicated formulation claims identified
Manufacturing coverage None apparent from the asserted claims
Combination therapy coverage Moderate; dependent claims add several established agents
Regulatory blocking power Limited; no conventional Orange Book listing effect
Biosimilar blocking power Limited to the claimed NMO use
Enforceability Dependent on proving the clinical indication, timing and treatment result
Design-around potential Meaningful, especially through different agents, disease settings or treatment objectives

The patent does not prevent manufacture or sale of C1-INH for hereditary angioedema. It also does not prevent use of C1-INH for unrelated complement disorders. Its economic value depends on whether acute C1-INH treatment becomes accepted and commercially used for NMO or NMOSD.

What formulations are protected by US Patent 10,786,557?

No formulation-specific protection appears in the listed claims.

The patent does not recite:

  • A particular excipient system.
  • A concentration or dose.
  • A lyophilized cake.
  • A reconstitution medium.
  • A container or delivery device.
  • A stability profile.
  • A manufacturing purification step.
  • A specific route such as intravenous infusion.

A competing manufacturer could therefore pursue a distinct formulation without avoiding the patent if it still practices the claimed NMO treatment method. Conversely, a formulation change alone may not avoid infringement if the product is administered in the claimed clinical setting.

Which companies are challenging the patent?

No conventional Paragraph IV challenge attaches to US Patent 10,786,557 because the patent is not an Orange Book-listed small-molecule patent. Publicly available patent records do not establish a reported Paragraph IV case directed to this patent.

Potential commercial challengers would more likely be:

  • A C1-INH manufacturer seeking an NMO indication.
  • A biosimilar or follow-on biologic sponsor.
  • A hospital or specialty pharmacy developing an acute NMO protocol.
  • A sponsor of an alternative complement inhibitor seeking to displace C1-INH.

A biosimilar sponsor may avoid direct method infringement by labeling and promotion that exclude NMO, although physician prescribing and induced-infringement questions would depend on the product label, promotional conduct and actual use.

What is the litigation status and settlement exposure?

The patent’s principal litigation risk is method-of-use enforcement rather than product-market exclusion.

A patentee would need to establish that the accused party:

  1. Administered or directed administration of C1-INH.
  2. Treated NMO or NMOSD.
  3. Used the product during an active attack or at attack onset.
  4. Intended to treat, prevent or delay progression.
  5. Satisfied the claim’s symptom-response limitation where required.
  6. Practiced any additional combination or timing limitation asserted.

The “pre-attack levels” requirement may complicate infringement proof. Medical records would likely be central. Evidence could include treatment protocols, physician instructions, infusion records, clinical trial materials, payer submissions and patient outcome assessments.

Settlement agreements could include:

  • A license limited to NMO treatment.
  • A covenant not to sue for clinical trials.
  • A field-of-use license for acute rescue treatment.
  • A label carve-out for non-NMO indications.
  • Royalty obligations tied to NMO sales.
  • Restrictions on promotion or protocol development.

No public settlement should be treated as established without a court filing, SEC disclosure or company announcement.

How does this patent compare with competing NMO drug estates?

The patent has a different risk profile from approved NMO therapies.

Therapy Sponsor or principal commercial holder Regulatory status Patent exposure relative to US 10,786,557
C1-INH/Cinryze Takeda-associated Cinryze franchise HAE prophylaxis, not NMO Directly implicated by claim 4 if used for NMO
Eculizumab/Soliris Alexion/AstraZeneca Approved for AQP4-positive NMOSD Listed biologic and method patents are separate from C1-INH claims
Inebilizumab/Uplizna Horizon Therapeutics, now within Amgen Approved for NMOSD Different target and treatment method
Satralizumab/Enspryng Roche/Genentech Approved for AQP4-positive NMOSD Different target and biologic pathway
Rituximab Multiple sponsors Off-label in many NMO settings Combination use may fall within claims 9-11 if C1-INH is also administered
Plasma exchange and IVIG Multiple providers Established acute-care modalities Combination claims 5-8 may be relevant when used with C1-INH

The patent is most relevant to a treatment protocol that combines C1-INH with existing acute-care or maintenance therapies. It does not threaten the core composition claims, manufacturing claims or approved indications of competing monoclonal antibodies.

What generic or biosimilar entry risks exist?

Generic entry risk is low in the Hatch-Waxman sense because C1-INH products are biologics. Biosimilar entry risk is separate and depends on:

  • Reference-product exclusivity.
  • Biosimilar approval timing.
  • Patent listings and certifications under the biologics framework.
  • Whether the biosimilar label includes NMO.
  • Whether the sponsor promotes NMO use.
  • Whether physicians use the product for NMO despite a carved-out label.

The patent could be asserted against a biosimilar sponsor whose label or promotional materials expressly recommend C1-INH for NMO. It is less likely to block a biosimilar marketed solely for hereditary angioedema if the sponsor avoids the claimed use.

What are the commercial implications and revenue exposure?

Revenue exposure is conditional rather than automatic. The patent does not cover the principal approved market for Cinryze, which is hereditary angioedema prophylaxis. Its value depends on whether NMO treatment becomes a reimbursed, protocolized use.

The principal commercial variables are:

  • Number of acute NMO and NMOSD attacks treated with C1-INH.
  • Adoption by academic neuroimmunology centers.
  • Evidence from controlled clinical studies.
  • Reimbursement for off-label biologic use.
  • Availability of competing approved NMOSD therapies.
  • Product supply and plasma-derived manufacturing capacity.
  • Physician preference for eculizumab, inebilizumab, satralizumab or rituximab.
  • Ability to prove treatment benefit against the pre-attack baseline.

Approved NMO therapies with disease-specific labels may reduce the commercial importance of a C1-INH method patent unless C1-INH demonstrates a distinct acute-rescue benefit, lower cost or clinical utility in treatment-refractory attacks.

Key Takeaways

  • US Patent 10,786,557 claims acute or onset treatment of NMO and NMOSD with C1-INH.
  • The most commercially specific claim is claim 4, which identifies Cinryze for NMO.
  • The patent does not claim C1-INH composition, formulation, manufacturing or broad complement inhibition.
  • Cinryze is FDA-approved for hereditary angioedema prophylaxis, not NMO.
  • The patent is not a conventional Orange Book barrier and does not create a standard Paragraph IV pathway.
  • Claims covering combination therapy with plasmapheresis, IVIG, rituximab, mycophenolate and eculizumab expand protocol-based exposure.
  • The “pre-attack levels” limitation may strengthen clinical specificity but creates claim-construction and proof issues.
  • Potential validity challenges center on obviousness, enablement, written description and indefiniteness.
  • Biosimilar risk is limited to products labeled, promoted or used for the claimed NMO treatment.
  • The estate’s commercial value depends on clinical adoption of acute C1-INH therapy in NMO and NMOSD.

FAQs

Can Cinryze be used for NMO without infringing US Patent 10,786,557?

Use during an acute NMO or NMOSD attack may fall within the patent claims if the other limitations are satisfied. Use for hereditary angioedema or an unrelated complement disorder is outside the stated claim scope.

Does claim 4 prevent use of recombinant C1-INH for NMO?

No. Claim 4 is limited to Cinryze, but claim 2, dependent on claim 1, covers human plasma-derived or recombinant C1-INH. Recombinant C1-INH may therefore raise issues under claims 1 and 2 if used in the claimed setting.

Can a physician be liable for administering C1-INH during an NMOSD attack?

Potentially, if the administration practices every limitation of an asserted claim. Direct infringement analysis would depend on the treatment facts, including timing, disease diagnosis and the claimed clinical outcome.

Does the patent cover preventive maintenance treatment between NMO attacks?

The claims focus on administration during an active attack or at attack onset. They do not clearly cover routine maintenance dosing between attacks absent facts bringing the treatment within the claim language.

Are eculizumab and C1-INH interchangeable under this patent?

No. Eculizumab is a different complement inhibitor and an approved NMOSD therapy. The patent becomes relevant only when C1-INH is administered in the claimed combination or treatment setting.

References

  1. United States Patent and Trademark Office. (2020). US Patent No. 10,786,557, methods of treating neuromyelitis optica with C1 esterase inhibitor. USPTO Patent Center and Patent Full-Text Database.

  2. U.S. Food and Drug Administration. (2023). Cinryze prescribing information. FDA.

  3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

  4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

  5. U.S. Food and Drug Administration. (2024). Soliris, Uplizna and Enspryng prescribing information. FDA.

More… ↓

⤷  Start Trial

Details for Patent 10,786,557

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Start Trial 2039-03-05
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 March 16, 2007 ⤷  Start Trial 2039-03-05
Takeda Pharmaceuticals U.s.a., Inc. CINRYZE c1 esterase inhibitor (human) For Injection 125267 October 10, 2008 ⤷  Start Trial 2039-03-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.